OKYO Pharma Limited (NASDAQ: OKYO) Set for 70% Surge

OKYO could be on the cusp of a significant breakout. We believe NASDAQ: OKYO could be a boomer trade with a potential 70% surge in sight, offering a compelling short-term opportunity while also holding long-term promise as a transformative player in the biotech and ophthalmology space.

Technical Overview
OKYO Pharma Limited (NASDAQ: OKYO) shares are down 7.33% in Monday's market trading. The stock’s Relative Strength Index (RSI) stands at 47, which, despite the recent decline, suggests that bullish momentum is building. The RSI is neither overbought nor oversold, indicating a healthy consolidation phase before a potential upward move.

For OKYO Pharma Limited (NASDAQ: OKYO) shares, the immediate support lies in the $0.926 pivot level not so far from the current price will serve as a springboard towards greater highs with eyes set on 70% gain as confirmed by the chart pattern.

Similarly, a breakout above the $1.55 resistant level could pave the way for the anticipated 70% surge on the horizon without testing the support point aforementioned above.

About OKYO Pharma Limited (NASDAQ: OKYO)
OKYO Pharma Limited (NASDAQ: OKYO) is a United Kingdom-based clinical-stage biopharmaceutical company, founded in 2007, that focuses on developing innovative therapeutics for inflammatory eye diseases and ocular pain. The company went public on May 17, 2022, and operates within the healthcare sector, specializing in ocular health advancements. OKYO is led by CEO Gary S. Jacob and a dedicated team, working to address unmet needs in ophthalmology.